tirzepatide 10mg side effects 20 Possible Long-Term to Be Aware Of Comparative safety and side effects
Description
Pipeline (Phase 3 trials completed, FDA decision pending as of April 2026): Survodutide (BI 456906): Dual GLP-1/glucagon agonist from Boehringer Ingelheim

it is in the pipeline already

Best Current Advice for Prevention/Recovery: Anticoagulation compliance

Retatrutide activates GLP-1, GIP, and glucagon, which regulate appetite, insulin, and metabolism
.jpg)
However, the exact mechanisms by which dual agonists enhance feeding suppression beyond GLP-1RAs remain unclear